# A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

Source: https://onco.cc/trials/nct07134088/  
OnCo record `nct07134088` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Blinatumomab in acute lymphoblastic leukaemia, run by Amgen, active and no longer recruiting.

## Summary

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia is a phase 1/2 interventional study registered as NCT07134088 by Amgen, with 104 participants enrolled, started 2025-12-08 and due to reach its primary completion in 2028-12-05. Interventions recorded: Blinatumomab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07134088
- Phase: 1/2
- Setting: A Phase 1b/2 Study to Investigate the Safety, Efficacy and Pharmacokinetics of Administration of Subcutaneous (SC) Blinatumomab in Pediatric Participants With Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+) B-Cell Precursor Acute Lymphoblastic Leukemia (B-ALL)
- Sponsor: Amgen
- Enrolled: 104

## Sources

- ClinicalTrials.gov NCT07134088: https://clinicaltrials.gov/study/NCT07134088

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/)
- drugs: [Blinatumomab](https://onco.cc/drugs/blinatumomab/)
- companies: [Amgen](https://onco.cc/companies/amgen/), [BeOne Medicines (formerly BeiGene)](https://onco.cc/companies/beone/)

---
JSON: https://onco.cc/api/v1/entities/nct07134088.json